The US Food and Drug Administration is to give a priority review to Arexvy, a vaccine for the prevention of respiratory syncytial virus (RSV) disease, in the new indication for adults from the ages of 50 to 59 years. Developed by GSK Plc, the vaccine is currently approved for adults 60 years and above. If authorised, Arexvy would be the first vaccine to help protect the new age group against lower respiratory tract disease caused by RSV.
